Please join us for a workshop on developing SBIR grants.
Thursday, January 24th, 2019 from 11 am - 1 pm
Lory Student Center
Longs Peak Room (#302)
Lunch Provided, Registration REQUIRED
You MUST register to receive the complimentary lunch. Registration closes at 50 participants.
11:00 am -11:30 am: Crash Course on Federal SBIR/STTR programs
11:30 am -12:15 pm: SBIR Awardees Panel
12:15 pm - 1:00 pm: Group Breakouts*
*Group Breakouts provide the opportunity to sit with individual panel members to discuss strategies, common pitfalls, other SBIR specifics.
Scott Fullbright, PhD
CEO and Co-Founder, Living Ink Technologies
NSF SBIR
Scott is the CEO and co-founder of Living Ink, a Colorado-based company developing eco-friendly
pigments for a variety of markets including ink, cosmetics, and plastics. Living Ink has raised a
combined $1.5M in federal and state grant programs. Prior to Living Ink, Scott spent the last 12
years in the algae bioproducts industry, where he led R&D projects in both industry and academia.
He received his PhD from Colorado State University in Cell and Molecular Biologies.
Tom Reilly, PhD
CSO and Co-Founder, Access Sensor Technologies
NSF, NIH, USDA, NOAA SBIR
Tom is a Ph.D. chemist with much of his research background involving functional materials, instrumentation and sensor development. He was the first hire at Access Sensor Technologies, a CSU spin-
out company formed in 2013. The company has been fortunate to receive funding for environmental
diagnostic concepts from the NSF, NIH-NIEHS, CDC-NIOSH, USDA and NOAA SBIR programs. Using SBIR
funds the company has advanced several early-stage concepts. To date, two product lines have been
brought to market that were funded in part through SBIR grants.
Brian Heinze, PhD
R&D Director, Optienz Sensors
NSF SBIR
Brian is R&D Director at OptiEnz Sensors where he leads technical development and grant based
fundraising activities. He earned a B.S. degree in biology and a Ph.D. in biosystems engineering, both
with honors from the University of Arizona. His dissertation, entitled “Optical Immunosensors for Pathogen
Detection,” was focused on designing portable optical antibody-based biosensors. Brian has been actively
involved in researching and developing optical biosensors for more than ten years. Previously, he worked
as a post-doctoral researcher at OptiEnz Sensors and a research scientist at Colorado State University.
He also operated a research consulting company that developed chemical sensors for defense-related
projects.
Rodman Tompkins
Director of Licencing and Business Development, CSU Ventures
Executive Vice President - Technology Strategy, Mantel Technologies
DoD SBIR
Rod joined CSUV in 2008 and is a Director of Licensing and Business Development for the
Infectious Disease portfolio, and an eclectic mix of other technologies ranging from neuroscience
and reproductive biology to atmospheric sciences. Rod co-founded and helps manage Mantel
Technologies, a government contracting start-up formed by CSU Ventures to actively transition
technologies that can be matched to specific government needs. Rod earned MS degrees in
neuroscience and infectious disease from CSU.
Richard Duke
CSO and Founder; Colorado Institute for Drug, Device and Diagnostic Development (CID4)
NIH SBIR
Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with 15
years of experience in building, financing, and managing start-up biotechnology companies based on
inventions made in Colorado’s non-profit research institutions. He is currently Co-scientific Founder,
President and CEO of ApopLogic Pharmaceuticals. Dr. Duke is a Co-scientific Founder and former CEO,
President and Director of GlobeImmune, Inc. and was involved in the formation of Sierra Neuropharmaceuticals where he was an initial Director. These Colorado-based companies have raised more than $150 million in financing and have multiple products in phase 1 and 2 human clinical trials. In addition to his entrepreneurial activities, Dr. Duke has over twenty-five years of experience in cutting-edge biomedical research and is a tenured faculty member in the Departments of Medicine (Medical Oncology) and Immunology at the University of Colorado Denver. Dr. Duke has provided independent 3rd-party research analysis in the life sciences sector to Janus Capital and to venture capital firms.
Event sponsored by: